{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:12:01Z","timestamp":1769598721061,"version":"3.49.0"},"reference-count":20,"publisher":"Informa UK Limited","issue":"34","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019402","name":"Puma Biotechnology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Genentech"},{"name":"Pfizer\/National Comprehensive Cancer Network"},{"name":"Cardinal Health Specialty Solutions"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,12,31]]},"DOI":"10.2217\/fon-2019-0537","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T14:23:36Z","timestamp":1572359016000},"page":"3935-3944","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Observational Study of Clinical Outcomes of Eribulin Mesylate in Metastatic Breast Cancer After Cyclin-Dependent Kinase 4\/6 Inhibitor Therapy"],"prefix":"10.1080","volume":"15","author":[{"given":"Sarah S","family":"Mougalian","sequence":"first","affiliation":[{"name":"Yale Cancer Center, Yale Medical School, New Haven, CT\u00c2\u00a006510, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, OH43017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[{"name":"Formerly with Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ\u00c2\u00a007677, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karenza","family":"Alexis","sequence":"additional","affiliation":[{"name":"Formerly with Eisai, Inc., Medical Affairs, Woodcliff Lake, NJ\u00c2\u00a007677, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debanjana","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ07677, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell L","family":"Knoth","sequence":"additional","affiliation":[{"name":"Formerly with Eisai, Inc., US Health Economics and Outcomes Research and Real World Evidence, Woodcliff Lake, NJ\u00c2\u00a007677, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damion","family":"Nero","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, OH43017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Miller","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, OH43017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djibril","family":"Liassou","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, OH43017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan K","family":"Kish","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions, Dublin, OH43017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Cancer Stat Facts . Female breast cancer. National Cancer Institute MD USA (2019). https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0889"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21349"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055"},{"key":"e_1_3_2_7_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Cancer Stat Facts . Female breast cancer subtypes. National Cancer Institute MD USA (2019). https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"key":"e_1_3_2_8_1","unstructured":"Pfizer . Ibrance (palbociclib) online material (2019). https:\/\/www.pfizerpro.com\/product\/ibrance?cbn=1-510216238:1-518669114#ref3"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1519500"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.5374"},{"key":"e_1_3_2_11_1","unstructured":"NCCN . NCCN Clinical Practice Guidelines in Oncology \u00e2\u20ac\u201c breast cancer (NCCN Evidence Blocks) version 1.2018 (2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_blocks.pdf"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7094"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0317"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0964"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.8748"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489063"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12482"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.6340"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00337-6"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:38Z","timestamp":1719125138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":20,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2019,12,31]]}},"alternative-id":["10.2217\/fon-2019-0537"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0537","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}